Published in Clinical Oncology Week, January 9th, 2006
Researchers in the United States conducted a study "to compare the combination of paclitaxel (Taxol) and topotecan (Hycamtin) with paclitaxel, carboplatin (Paraplatin; Bristol-Myers Squibb), and etoposide (Etopophos, VePesid) in patients with previously untreated extensive-stage small cell lung cancer."
"In this phase II trial, 120 patients were randomly allocated to receive either topotecan (1.5 mg/m2 i.v. days 1, 2, and 3) and paclitaxel (175 mg/m2 i.v.day 1) every 21 days or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.